DiaMonTech AG
DiaMonTech AG is a Berlin-based medtech company developing non-invasive blood glucose monitoring devices using proprietary mid-infrared laser and photothermal detection technology, targeting diabetes patients, healthcare providers, and health-conscious consumers across Europe and the United States.
- Company typePrivate
- Founded2015
- HeadquartersBerlin, Germany
- Headcount11–50
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What DiaMonTech AG does
DiaMonTech AG is a Berlin-based medical device company founded in 2015 that is developing non-invasive blood glucose monitoring technology based on mid-infrared quantum cascade laser (QCL) spectroscopy combined with its patented Infrared Evaluated Photothermal Detection (IRE-PTD) method. The technology scans interstitial fluid in the skin, where glucose levels run at 85–90% of blood glucose and follow changes within approximately five minutes, and detects temperature changes of less than 1/1000 of a degree Celsius to deliver a reading in 10–15 seconds without needles, test strips, or consumables. Clinical studies have reported MARD values of 11.1–20.7% and 99.1% accuracy per Consensus Error Grid Analysis across 100+ participants, comparable to early FDA-approved continuous glucose monitors.
The product portfolio consists of the CE-certified DMT Base for professional diabetes center environments, the D-Pocket handheld consumer device (smartphone-sized, targeted for 2026 launch), the D-Sensor miniaturized wearable being co-developed with Samsung for smartwatch integration, and the Diamoki companion app for longitudinal tracking of glucose, blood pressure, diet, activity, BMI, and medication. The company holds ISO 13485:2016 and ISO 27001 certifications, has filed an FDA pre-submission for the D-Base, and protects its technology with more than 100 patents globally.
DiaMonTech's business model centers on hardware sales (B2B to diabetes centers and B2C to patients and health-conscious consumers), with a strategic push toward reimbursement-driven revenue through health insurance partnerships (notably HanseMerkur) and future recurring software/data value via the Diamoki app. Total funding raised exceeds €32 million across rounds spanning 2018–2025, anchored by Samsung Ventures/Samsung Next, Bioventure, IBB Ventures, Unorthodox Ventures, Moll Family GmbH, and Companisto. The company remains pre-commercial with flagship consumer launch planned for 2026.
DiaMonTech AG firmographics
Firmographics- Name
- DiaMonTech AG
- Legal name
- DiaMonTech AG
- Website
- https://diamontech.de
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- DiaMonTech AG is a Berlin-based medtech company developing non-invasive blood glucose monitoring devices using proprietary mid-infrared laser and photothermal detection technology, targeting diabetes patients, healthcare providers, and health-conscious consumers across Europe and the United States.
- Ownership category
- akta.pro rank
DiaMonTech AG industry classification
Industry- Product category
- Medical Devices / Non-Invasive Blood Glucose Monitoring
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Blood Glucose Monitoring (BGM) Meters & Test Strips (HLAHAHAG)
- akta.pro secondary industries
- Continuous Glucose Monitoring (CGM) Systems (HLAHAHAA), Blood Glucose & Metabolic POCT (Glucose, Ketones, Lactate) (HLAHAOAB), Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers) (CRACAQAE)
Keywords
Where DiaMonTech AG is headquartered
LocationHeadquarters
- HQ city
- Berlin
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
DiaMonTech AG business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Hardware Sales - D-Pocket: Sale of portable non-invasive blood glucose monitoring devices (D-Pocket) to consumers and healthcare providers. Device is smartphone-sized and designed for personal use. No consumables required.
- Hardware Sales - D-Base/DMT Base: Sale of professional-grade non-invasive glucose monitoring device optimized for use in diabetes centers and clinical settings. CE-certified medical device.
- D-Sensor Wearable Technology: Future revenue stream from miniaturized sensor technology for integration into smartwatches and wearables. Currently in development with Samsung.
- Diamoki App - Companion Software: Diabetes management companion app for tracking blood glucose, blood pressure, diet, activity, weight/BMI and medication. App can import data from health apps and glucose meters. Currently under development.
- Strategic Healthcare Partnerships: Strategic cooperation with health insurance companies like HanseMerkur for providing non-invasive blood glucose measurement services to insured individuals. Potential for reimbursement-driven revenue.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | One time/ perpetual license | D-Pocket - Consumer Device |
| Other | One time/ perpetual license | D-Base - Professional Device |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels7 records
DiaMonTech AG product offering
Product offeringCore offering
DiaMonTech AG develops and is commercializing medical devices for non-invasive blood glucose measurement using proprietary mid-infrared quantum cascade laser spectroscopy and its patented IRE-PTD photothermal detection method. Its current portfolio includes the CE-certified DMT Base for professional clinical settings, the in-development D-Pocket handheld consumer device, the in-development D-Sensor miniaturized wearable sensor (co-developed with Samsung), and the Diamoki companion health-tracking app.
Product overview
DiaMonTech AG offers a portfolio of non-invasive blood glucose monitoring products built on its proprietary mid-infrared quantum cascade laser (QCL) technology and patented IRE-PTD (Infrared Excited — Photothermal Detection) method. The core product line consists of three distinct devices: the DMT Base, a CE-certified stationary device for professional clinical environments (diabetes centers); the D-Pocket, a handheld consumer device approximately the size of a smartphone — the flagship portable product currently in development; and the D-Sensor, a miniaturized wearable sensor being developed in partnership with Samsung for integration into smartwatches. These devices share a common underlying technology platform — mid-infrared spectroscopy scanning interstitial fluid in the skin to detect glucose molecules via a heat-wave detection process — but serve different form factors and market segments. Complementing the hardware products, the companion mobile app Diamoki enables users to track glucose, blood pressure, diet, activity, weight/BMI, and medication, with automatic import from health apps and glucometers, providing a unified data analytics layer across the product ecosystem. The company also holds ISO 13485:2016 and ISO 27001:2017 certifications, and has filed over 100 patents globally.
Differentiator
Problem solved
Functional benefit
Brands
- D-Pocket: Handheld non-invasive blood glucose monitoring device, smartphone-sized, currently in development. Uses mid-infrared laser technology and photothermal detection for pain-free glucose measurement.
- D-Sensor
- Diamoki
- DMT Base
Products and services
- DMT Base (D-Base) Non-invasive, CE-certified medical device for professional blood glucose monitoring using mid-infrared QCL laser spectroscopy and patented IRE-PTD photothermal detection. Designed for diabetes centers and clinical settings, providing needle-free, consumable-free glucose measurement with 99.1% clinical accuracy.
- D-Pocket Handheld, smartphone-sized, non-invasive blood glucose monitor for consumer use. Uses patented mid-infrared QCL + IRE-PTD technology to deliver pain-free glucose readings within 10–15 seconds without test strips or other consumables. Achieves clinical-grade accuracy comparable to early invasive CGM devices (MARD 20.7% and 19.6%).
- D-Sensor Miniaturized non-invasive glucose sensor under development with Samsung for integration into smartwatches and wearable devices. Extends DiaMonTech's mid-infrared laser and photothermal detection technology into a continuous-monitoring form factor for both diabetes patients and health-conscious users.
- Diamoki Companion mobile app for diabetes management that tracks blood glucose, blood pressure, diet, activity, weight/BMI, and medication, with automatic import from health apps and glucose meters. Provides trend visualization and structured health-data analytics as the software layer across DiaMonTech's device ecosystem.
Quantifiable outcome
- MARD (Mean Absolute Relative Difference) values of 20.7% and 19.6% - comparable to early invasive CGM devices approved by FDA and Notified Body in EU
- +4 more outcomes
Companies that use DiaMonTech AG
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles3 records
DiaMonTech AG technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
DiaMonTech AG partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- German Accelerator Life Sciences ProgramcoreMarket access initiative for life sciences startups to assist in US market navigation, providing expert mentorship and strategic connections. Supports DiaMonTech's international expansion goals.
- HanseMerkurcoreOne of Germany's largest private health insurance companies (€2.3 billion annual revenue) plans strategic cooperation to provide non-invasive blood glucose measurement to insured customers. First pilot projects for insulin-dependent diabetics planned for 2021. HanseMerkur sees potential for early diabetes detection using DiaMonTech technology.
Scale indicators9 records
Recent moves7 records
Expansion highlights6 records
DiaMonTech AG competitors and assessment
Company assessmentBroad incumbents
- Dexcom: Leading CGM manufacturer (G6, G7) with the strongest accuracy credentials (MARD ~8%) and deepest payer/reimbursement relationships. Broad incumbent and the gold-standard comparison point for any non-invasive entrant; could pursue non-invasive R&D leveraging its clinical evidence base.
- Roche Diabetes Care: Manufacturer of Accu-Chek blood glucose meters and one of the largest traditional BGM incumbents globally. Broad incumbent in glucose monitoring with established pharmacy distribution; potential competitor if the company pursues non-invasive BGM replacement or partners with non-invasive entrants.
- Abbott Diabetes Care: Manufacturer of FreeStyle Libre, the dominant CGM with 5M+ global users and established retail/payer distribution. Broad incumbent in glucose monitoring that DiaMonTech positions itself against in accuracy comparisons; any Abbott move into non-invasive would directly threaten DiaMonTech's window.
- Medtronic Diabetes: Major medical device incumbent offering Guardian Connect CGM and insulin pumps. Broad incumbent in diabetes care with substantial R&D resources and integrated insulin-delivery ecosystem; any pivot to non-invasive CGM would directly compete with DiaMonTech's professional and consumer offerings.
Emerging players
- Afon Technology: Welsh startup developing a non-invasive wearable continuous glucose monitor using proprietary electromagnetic sensing. Early-stage peer pursuing similar miniaturized, no-consumable, continuous monitoring vision as DiaMonTech's D-Sensor program, providing comparable technology-risk profile.
- Senseonics: Developer of Eversense, the only implantable long-term CGM (180-day sensor). Emerging player pursuing alternative continuous monitoring approaches with comparable accuracy to traditional CGMs but via invasive subcutaneous implantation — represents adjacent technology risk if DiaMonTech's non-invasive accuracy falls short.
- LifePlus: Developer of LifeLeaf, a non-invasive continuous glucose monitoring wearable. Emerging player pursuing similar smartwatch/wearable form factor as DiaMonTech's D-Sensor, though at earlier commercialization stage with different underlying technology.
Direct peers
- Know Labs: US-based company developing non-invasive glucose monitoring using radiofrequency spectroscopy and its Bio-RFID sensor technology. Closest direct peer to DiaMonTech given its focus on truly non-invasive continuous glucose monitoring for consumer use, pursuing similar FDA pathways and consumer launch timeline.
- Nemaura Medical: UK-based developer of sugarBEAT, a non-invasive continuous glucose monitor using a disposable skin patch. Direct competitor in the non-invasive glucose monitoring space targeting both consumer wellness and medical-grade applications, providing useful comparability on regulatory timelines and consumer adoption rates.
- Integrity Applications (GlucoTrack): Israeli company that developed GlucoTrack, a non-invasive glucose monitor combining ultrasonic, electromagnetic, and thermal sensors for ear-clip measurement. Direct peer despite using different sensing modalities — represents the long history of attempted non-invasive glucose commercialization.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
DiaMonTech AG social profiles
Digital presenceDiaMonTech AG compliance and trust
Trust signalCompliance3 records
DiaMonTech AG financial estimates
Financial estimateRevenue estimate
Valuation estimate
DiaMonTech AG leadership team
Management profileNumber of profiles
Profiles11 records
DiaMonTech AG funding detail
Funding detailFunding overview
Funding rounds10 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DiaMonTech AG M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DiaMonTech AG
What does DiaMonTech AG do?
DiaMonTech AG develops and is commercializing medical devices for non-invasive blood glucose measurement using proprietary mid-infrared quantum cascade laser spectroscopy and its patented IRE-PTD photothermal detection method. Its current portfolio includes the CE-certified DMT Base for professional clinical settings, the in-development D-Pocket handheld consumer device, the in-development D-Sensor miniaturized wearable sensor (co-developed with Samsung), and the Diamoki companion health-tracking app.
Is DiaMonTech AG a public or private company?
DiaMonTech AG is a private company. It is classified as venture growth investor backed and is currently operating.
When was DiaMonTech AG founded?
DiaMonTech AG was founded in 2015. It employs 11 to 50 people.
Where is DiaMonTech AG based?
DiaMonTech AG is headquartered in Berlin, Germany, in the Europe region.
How does DiaMonTech AG make money?
Five revenue lines are on record. Hardware Sales - D-Pocket is the primary driver. The others are hardware Sales - D-Base/DMT Base, D-Sensor Wearable Technology, diamoki App - Companion Software and strategic Healthcare Partnerships.
Who are DiaMonTech AG's main competitors?
Broad incumbents on record are Dexcom, Roche Diabetes Care, Abbott Diabetes Care and Medtronic Diabetes. Emerging players are Afon Technology, Senseonics and LifePlus. Direct peers are Know Labs, Nemaura Medical and Integrity Applications (GlucoTrack).
Does DiaMonTech AG have an API?
No public API is recorded for DiaMonTech AG.
What industry is DiaMonTech AG in?
DiaMonTech AG's product category is Medical Devices / Non-Invasive Blood Glucose Monitoring. Its primary akta.pro industry code is HLAHAHAG, Blood Glucose Monitoring (BGM) Meters & Test Strips, with a secondary code of HLAHAHAA, Continuous Glucose Monitoring (CGM) Systems. Its NAICS code is 334510 and its SIC code is 3845.